Molecule Details
| InChIKey | OOUGLTULBSNHNF-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.61 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB05016 |
|---|---|
| Drug Name | Ataluren |
| CAS Number | 775304-57-9 |
| Groups | approved withdrawn |
| ATC Codes | M09AX03 |
| Description | Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patient... |
Categories: Musculo-Skeletal System OAT1/SLC22A6 inhibitors OAT3/SLC22A8 Inhibitors OATP1B3 inhibitors Oxazoles UGT1A9 Substrates
Cross-references: ChEBI: 94805 CHEMBL256997 ChemSpider: 9394889 D09323 PDB: JBF PharmGKB: PA166151864 PubChem:11219835 PubChem:175426931 Wikipedia: Ataluren ZINC: ZINC000013831791
Target Activities (2)
DrugBank Target Actions (5)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q4U2R8 | SLC22A6 | Solute carrier family 22 member 6 | inhibitor | enzymes |
| Q8TCC7 | SLC22A8 | Organic anion transporter 3 | inhibitor | enzymes |
| Q9NPD5 | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | inhibitor | enzymes |
| O60656 | O60656 | UDP-glucuronosyltransferase 1A9 | substrate | enzymes |
| P11532 | P11532 | Dystrophin | modulator | targets |